Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sorghum halepense pollen is an allergenic extract derived from Johnson grass (Sorghum halepense) pollen. [3] It is used for both allergy testing (diagnosis) and allergen-specific immunotherapy (hyposensitization therapy) to treat patients with allergic reactions to this specific pollen. [1, 17] Developed and marketed by ALK-Abelló, Inc., this non-standardized extract has been available since 1965. It is administered as a subcutaneous injection solution. [6] The product works by modulating the immune system to induce desensitization to the allergens present in Sorghum halepense pollen. [1] It is indicated for individuals with a confirmed clinical sensitivity to Johnson grass pollen, as determined by patient history and diagnostic skin testing, who suffer from conditions like allergic respiratory diseases. [8, 9]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Sorghum halepense pollen.